Connect with us

Spread & Containment

Mould, pesticides, toxic chemical exposures reported in survey of Canadian child care professionals

Nearly half of some 2,000 professionals in child care programs across Canada report unhealthy conditions for children, according to survey data released…

Published

on

Nearly half of some 2,000 professionals in child care programs across Canada report unhealthy conditions for children, according to survey data released on national Healthy Environments for Learning Day (HELD).  

Credit: CPCHE/CCCF

Nearly half of some 2,000 professionals in child care programs across Canada report unhealthy conditions for children, according to survey data released on national Healthy Environments for Learning Day (HELD).  

Educators, support staff, administrators and others in oversight roles replied to the survey on a wide range of environmental health and sustainability topics, conducted in March and April by the Canadian Partnership for Children’s Health and Environment (CPCHE) and the Canadian Child Care Federation (CCCF), in collaboration with University of Ottawa researchers.

More than two-thirds of respondents expressed concern about risks to children’s health and well-being posed by air pollution (indoor 64%; outdoor 69%), toxic chemicals in products (69%), a lack of access to nature (68%), and climate change (68%). 

More than half (53%) cited lack of funding and 45% cited lack of support from government as barriers to action to improve environmental health protection and sustainability in their program. 

The findings suggest that while child care professionals believe it is important for program settings to become healthier and more ecologically sustainable, the sector lacks the resources and supports to make needed changes. 

Against this backdrop, and to mark Healthy Environments for Learning Day, CPCHE, CCCF and more than 40 organizations across Canada jointly released a Vision for Healthy and Sustainable Child Care Environments in Canada, setting out 10 key areas for action.

Survey findings

Respondents to the national survey were asked about environmental health conditions in their child care settings. Among the findings:

  • 22% reported mould or a mouldy smell
  • 29% reported noticeable air pollution or fumes (e.g., from renovations, nearby industry, business or roadway)
  • 23% reported structural disrepair such as a leaking roof
  • 31% reported peeling paint on walls, woodwork or other surfaces
  • 33% reported windows that don’t open in rooms where children spend time
  • 30% reported having basement areas where children spend time
  • only 20% reported that their program had been tested for radon gas (a potent lung carcinogen that comes from uranium in soil and rock); 42% indicated that radon testing had not been done; 38% were unsure 
  • 29% reported excessive noise (e.g., from nearby roadway, industrial facility or airport)
  • 35% reported that their program had been affected by wildfire smoke in the past two years
  • 25% reported an insect infestation in the past year
  • 26% reported a rodent infestation in the past year
  • 22% reported pesticides used indoors on a routine basis
  • 22% reported lawn or garden pesticides/herbicides used on a routine basis

“These findings are concerning. A striking proportion of respondents are telling us about child care spaces with mould, structural disrepair, peeling paint, pest infestations, routine use of pesticides, and noticeable air contaminants from nearby traffic or industry,” says Erica Phipps, CPCHE’s Executive Director. “As a society, we need to do better than this. If we are serious about ensuring that all children in Canada get the best possible start towards lifelong health and success in learning, we need to invest in the child care settings where many spend significant portions of their formative early years.” 

“An ever-growing body of scientific research tells us that ongoing exposure to even low levels of some toxicants can permanently alter the developing brains and bodies of children,” Phipps adds. 

While 73% of respondents say there is top-level support (e.g., from the child care administrator/board/owner), interest among staff (71%), and support from families (72%) to improve environmental health and sustainability in their child care programs, action is so far limited. When queried on a host of available measures to reduce children’s exposures to toxic chemicals and pollution, conserve energy or otherwise improve the program’s ecological sustainability, the majority of respondents reported that actions were only partially implemented or not yet underway. 

Says Don Giesbrecht, CEO of the Canadian Child Care Federation: “This survey taps into the real-life experiences and knowledge of people working day-in and day-out in child care programs across Canada. We need to listen to their concerns and respond to these environmental health issues. It clearly shows why the Canada-wide child care plan is so necessary. Moving forward, more investment at the provincial/territorial and federal government levels are needed to create child care spaces that actively promote children’s health and well-being.”

A gap between commitment and capacity

“This survey speaks to the gap between commitment and capacity,” he adds. “People in our sector believe health and environment are important and want to see these changes. We just need to get the right policies and supports in place to enable it to happen.”

The results contribute to a renewed national dialogue sparked by nationwide federal-provincial/territorial child care investment agreements.

Progressive measures to improve environmental health and sustainability

Asked about a range of progressive measures to create healthier and more sustainable child care settings, respondents reported that their programs are currently taking action, including:

  • ensuring children have regular access to green/natural play space (55%)
  • reducing/avoiding the use of cleaning products that contain hazardous chemicals, other than those required to meet public health standards (45%)
  • choosing/using toys and crafts supplies that do not contain toxic chemicals (44%)
  • ensuring adequate shade (47%), 
  • minimizing the use of pesticides (49%) and 
  • ensuring a fragrance-free environment (43%)

Other measures, such as reducing vehicle idling or taking action to reduce carbon emissions, saw much lower levels of reported action. 

Across all of the potential measures, at least 1 in 10 respondents, and sometimes up to 3 in 10, reported that they are not yet doing an action but are interested. For example, 25% reported interest but not yet action to conserve energy. Similarly, 22% reported not reducing the use of plastics, but expressed interest in doing so. 

The survey findings suggest that climate change is the topic with the largest gap between level of concern and action. Only one in five respondents (20%) reported their child care program is taking action to reduce carbon emissions/address climate change, the lowest response rate across all measures surveyed. Yet, more than two-thirds (68%) of respondents indicated that they are very or somewhat concerned about the impact of climate change on children’s current and future health and well-being.

Additional survey insights:

Action on COVID

Surprisingly, fewer than half (46%) of respondents said that their child care program had taken measures to increase ventilation or otherwise improve indoor air quality in response to the COVID pandemic. Among the respondents who reported measures had been taken, opening windows more frequently was the most commonly cited action (67%), followed by use of portable (e.g., HEPA) air cleaning devices (53%). As a concerning indicator that information on safe and effective measures is not reaching practitioners, nearly one in twelve respondents (7%) reported the use of ozone air purifiers, devices for which Health Canada issued an interim order in 2021 to avoid use due to health risks. Similarly, 12% of respondents reported use of “fogging” devices that propel disinfecting/sanitizing chemicals into the air, a concerning practice that can increase inhalation of such chemicals by children and staff, and that is not known to be an effective means of reducing COVID transmission. 

Not all child care settings are equal

Child care professionals who indicated that the majority of children in their care are living in low-income circumstances were more likely to report unhealthy conditions in their programs. Respondents working in programs in which a majority of children are on low income were more likely to report structural disrepair, lead in water supply pipes, recent insect and/or rodent infestation, mould or mouldy smell, excessive moisture, peeling paint, noticeable air pollution and/or excessive noise from a nearby roadway, industrial facility or other source, and the use of artificial air fresheners, among others. 

Unregulated/unlicensed status was also significantly correlated with respondent-reported structural disrepair, having windowless rooms where children spend time, recent rodent infestation, routine use of pesticides indoors, use of cleaning/sanitizing/disinfecting chemicals in close proximity to children, and lack of natural vegetation in outdoor play areas. 

Conversely, respondents who reported that their child care program has outdoor spaces with natural vegetation were more likely to be working in regulated child care, and in programs serving a low proportion of children who live on low income, are visible minorities or who speak a language other than English or French at home.

Respondents working in regulated child care were more likely to report that their program had taken measures to improve ventilation and air quality in response to the COVID pandemic.

Child health consequences

There is ever-increasing scientific evidence that children’s exposures to toxic chemicals and pollutants, prenatally and in childhood, adversely affect their cognitive development, contribute to learning and behavioural challenges, and affect their educational pathways and lifelong health trajectories (Bennett et al, 2016). 

Early environmental exposure to pollutants and toxic chemicals are implicated in the development of chronic diseases, including cancer, cardiovascular disease, asthma, diabetes, and neurodegenerative diseases (Clark et al, 2020; Cooper et al, 2011).

CPCHE and CCCF launch online resource for child care professionals

In the lead-up to Healthy Environments for Learning Day, CPCHE and CCCF launched an online information hub and checklist offering child care professionals a host of practical tips and supporting information to improve environmental health and ecological sustainability in their programs. Survey findings indicate that such supports are needed: nearly nine out of 10 survey respondents expressed interest in using such a resource; 47% cited the lack of information, guidance and training as a current barrier to action. 

Towards a national vision of healthy and sustainable child care environments

To further mark national Healthy Environments for Learning Day, CPCHE, CCCF and more than 40 organizations across Canada released Healthy and Sustainable Child Care Environments: A Vision for Canada. 

It outlines 10 priority actions, including reducing toxic exposures, fostering children’s access to natural play spaces, creating culturally inclusive settings, and taking action on climate change through building design/operations, energy conservation and uptake of renewable energy sources. 

“I fully believe that Canada can achieve a world-class child care system that supports all children to thrive, models best practices on climate change, and fosters the child-nature connections that we know are so important for children’s emotional well-being and their future role as environmental stewards,“ says Giesbrecht. We want to see action towards the Vision, and our sector is keen to do our part.”

Further comments on the national Vision

“Children have a right to grow up in healthy learning environments and this is why governments must give special attention to the health and safety of children as they build the new Canada-wide system of early learning and child care. Child Care Now, Canada’s national child care advocacy association, endorses the ambitious vision and recommendations for healthy and sustainable child care environments developed by the Canadian Partnership for Children’s Health and Environment and the Canadian Child Care Federation. They will serve children, parents and communities for decades to come.”

  • Morna Ballantyne, Child Care Now

“Here in BC, we are recommending concrete policy changes that would advance key elements of this national vision statement. Our aim is to hasten BC’s transition to both universal child care and a clean economy in ways that improve the health and well-being of children, families, educators, and communities.” 

  • Sharon Gregson, Coalition of Child Care Advocates of BC

“In an increasingly uncertain world, we need to do all we can to honour our children by creating safe and nurturing spaces in which they can learn, grow and thrive. If, as a society, we take the actions outlined in this Vision for Healthy and Sustainable Child Care Environments, we will be doing just that.”  

  • Raffi Cavoukian, Raffi Foundation for Child Honouring

“Outdoor Play Canada welcomes and supports this national Vision Statement as a framework for collective action that will guide child care settings across Canada to optimize children’s well-being. There is unequivocal evidence that children benefit from routine outdoor learning and play, and connections with nature. Investing in healthy child care settings that afford ample access to outdoor play and the natural world will benefit children today and in generations to come. This Vision Statement supports the need for jurisdictional policy amendments to allow, accommodate, facilitate and encourage outdoor play as a healthy foundational feature of child care environments and delivery systems”

  • Dr. Mark Tremblay, Chair, Outdoor Play Canada; Senior Scientist, CHEO Research Institute.

* * * * *

About   

The Canadian Partnership for Children’s Health and Environment (CPCHE): healthyenvironmentforkids.ca/about/

The Canadian Child Care Federation (CCCF): cccf-fcsge.ca

Healthy Environments for Learning Day (HELD): healthyschoolsday.ca


Read More

Continue Reading

Government

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

Up to 40,000 Army National Guard troops – around 13% of the force…

Published

on

40,000 National Guard Troops Face Unemployment As Vaccine Deadline Imminent

Up to 40,000 Army National Guard troops - around 13% of the force - could be fired for not getting the mandated COVID-19 vaccine (which has limited efficacy against Omicron, doesn't stop transmission, has been linked to elevated heart problems, and has been mandated for a healthy demographic that rarely dies of the disease).

Michigan Army National Guard Sgt. Mark Abbott administers a COVID-19 vaccine

Guard soldiers have until Thursday to get the jab, according to the Associated Press, which notes that between 20% and 30% of Guard soldiers in six states remain unvaccinated.

"We’re going to give every soldier every opportunity to get vaccinated and continue their military career. Every soldier that is pending an exemption, we will continue to support them through their process," Lt. Gen. Jon Jensen, director of the Army National Guard, told AP. "We’re not giving up on anybody until the separation paperwork is signed and completed. There’s still time."

Last year, Defense Secretary Lloyd Austin ordered all service members to get the vaccine, with different branches maintaining different deadlines for the jab. The Army National Guard was given the maximum amount of time, largely because its roughly 330,000 soldiers are scattered throughout the country, including remote locations.

The Army Guard’s vaccine percentage is the lowest among the U.S. military — with all the active-duty Army, Navy, Air Force and Marine Corps at 97% or greater and the Air Guard at about 94%. The Army reported Friday that 90% of Army Reserve forces were partially or completely vaccinated.

The Pentagon has said that after June 30, Guard members won’t be paid by the federal government when they are activated on federal status, which includes their monthly drill weekends and their two-week annual training period. Guard troops mobilized on federal status and assigned to the southern border or on COVID-19 missions in various states also would have to be vaccinated or they would not be allowed to participate or be paid. -AP

Complicating matters is a rule that Guard soldiers deployed on state active duty may not require a vaccination, depending on state-level mandates. 

According to the report, at least seven governors have asked Austin to reconsider, or drop, the vaccine mandate for National Guard members - with some having filed or joined lawsuits to that end.

Austin, apparently following his own special brand of science, told them to pound sand, saying that Covid-19 "takes our service members out of the fight, temporarily or permanently, and jeopardizes our ability to meet mission requirements," adding that troops will either need to get vaccinated or lose their Guard status.

"When you’re looking at, 40,000 soldiers that potentially are in that unvaccinated category, absolutely there’s readiness implications on that and concerns associated with that," said Jenson, adding "That's a significant chunk." 

AP reports that around 85% of Army Guard soldiers are fully vaccinated, while 87% are at least partially vaccinated.

Tyler Durden Sun, 06/26/2022 - 18:00

Read More

Continue Reading

Government

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

Authored by Zachary Stieber via The Epoch Times…

Published

on

CDC Confirmed Post-Vaxx Death From Blood-Clotting Two Weeks Before Alerting Public: Emails

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

The Centers for Disease Control and Prevention (CDC) confirmed in late 2021 that a person died from blood clotting after receiving a COVID-19 vaccine that had been linked with an increased risk of blood clotting, but did not alert the public for two weeks, newly obtained emails show.

A general view of the Centers for Disease Control headquarters in Atlanta, Ga., on April 23, 2020. (Tami Chappell/AFP via Getty Images)

Dr. Tom Shimabukuro, a CDC official, told colleagues at the CDC and the Food and Drug Administration (FDA) on Dec. 2, 2021, “We have confirmed a 9th TTS death following Janssen vaccination,” according to emails obtained by The Epoch Times through a Freedom of Information Act request.

TTS refers to thrombosis with thrombocytopenia syndrome, a condition that features low platelet levels combined with blood clots.

Officials had recommended a nationwide pause on the administration of the vaccine, produced by Johnson & Johnson (J&J) subsidiary Janssen, in April 2021 after six women experienced TTS after J&J vaccination and three died. But they lifted the pause after determining the vaccine remained safe and effective.

The condition was not discussed much in the ensuing months, despite the CDC later reporting that five additional deaths occurred before Aug. 31, 2021. Shimabukuro gave a single update, in mid-October 2021, saying five total deaths had been reported.

That was until December 2021. Twelve days after Shimabukuro alerted colleagues of the ninth death, the FDA urged healthcare workers not to administer the vaccine to people with certain conditions because of the TTS risk. Two days after that, Dr. Isaac See, another CDC official, informed the public during a meeting that nine deaths had occurred post-vaccination.

It’s unclear when the CDC learned of the sixth, seventh, and eighth deaths.

The CDC takes reports made to the Vaccine Adverse Event Reporting System and attempts to confirm the reports, including post-vaccination deaths. A higher number of post-vaccination TTS deaths have been reported to the system than the number the CDC has verified.

One day after Shimabukuro confirmed the ninth death, his message was forwarded by Dr. Amanda Cohn, another CDC official, to CDC Director Dr. Rochelle Walensky.

“See below, information on a 9th completely tragic death from TTS,” Cohn wrote.

Many thanks for letting us know … any tragic case,” Walensky responded.

The emails were partially redacted; one was fully redacted.

Read more here...

Tyler Durden Sun, 06/26/2022 - 15:30

Read More

Continue Reading

Spread & Containment

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug…

Published

on

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is moving steadily northbound with power after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin).  

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. Microcapdaily has been reporting on IPIX for a long time and we were there when the stock (then trading as CTIX) made a legendary run skyrocketing to $4.93 per share. 

Subscribe To Our 100% Free Penny Stock Newsletter!

Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) is a clinical stage pharmaceutical company developing innovative therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The Company owns the rights to Brilacidin, its lead drug in a new class of compounds called defensin-mimetics, and Kevetrin (thioureidobutyronitrile), its anti-cancer compound. Brilacidin is being studied by the Company, as well as other independent researchers, as a potential broad-spectrum antiviral therapeutic for the treatment of viruses including the novel coronavirus (SARS-CoV-2), which is responsible for COVID-19. 

Brilacidin is Innovation Pharma’s lead drug candidate in its Host Defense Protein (HDP)-mimetic franchise. Brilacidin has been granted Fast Track designation by the FDA and currently is being evaluated in a randomized, placebo-controlled Phase 2 clinical trial in hospitalized COVID-19 patients (see NCT04784897). Two independent Machine Learning (AI) studies also identified Brilacidin as one of the most promising inhibitors of SARS-CoV-2, the virus responsible for COVID-19, based on Brilacidin’s molecular properties. Modeled after HDPs, the “front-line” of defense in the body’s innate immune system, it is a synthetic, non-peptidic small molecule that kills pathogens swiftly, significantly reducing the likelihood of drug resistance developing. Just as importantly, Brilacidin functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. 

Kevetrin is a small molecule that has demonstrated the potential of becoming a breakthrough cancer treatment by inducing activation of p53, a protein frequently referred to as the “Guardian of the Genome” due to its critical role in controlling cell mutations. In most cancers, regardless of origin, type, and location, the p53 pathway becomes inactivated (dysfunctional), thus preventing the body from performing its natural anti-tumor functions. The TP53 gene is the most studied gene of all time. Conducted at the Dana-Farber Cancer Institute and at Beth Israel Deaconess Medical Center, a Phase 1 clinical trial evaluating Kevetrin in treating Advanced Solid Tumors has been successfully completed, with patients showing good toleration and encouraging signs of potential therapeutic response. The Company has concluded its open-label, dose-escalation Phase 2a trial of Kevetrin in Platinum-Resistant/Refractory Ovarian Cancer. Highly encouraging preliminary data from the first patients treated in the trial showed modulation of the p53 protein in response to administration of Kevetrin. With a promising bioavailability profile, and to leverage its short half-life (the drug exits the body in approximately 8 to 10 hours), efforts are underway to develop Kevetrin as an oral anti-cancer agent (tablet or capsule) that can be administered daily, potentially even multiple times per day. The FDA has awarded Kevetrin Orphan Drug status for Ovarian Cancer, Pancreatic Cancer, and Retinoblastoma, qualifying it for developmental incentives and an extra 7 years of market exclusivity upon drug approval. The FDA also has granted Kevetrin Rare Pediatric Disease designation for childhood Retinoblastoma. 

Microcapdaily has been covering IPIX for years starting with CTIX back in 2015 reporting on the stocks legendary run to $4.93 per share. We stated on CTIX back in the day: “As anyone in the industry knows, regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with no success thus far. It seems Kevetrin(TM) has accomplished this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. The market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually, he adds.”

IPIX has established a valuable intellectual property portfolio: 

To Find out the inside Scoop on IPIX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IPIX

On June 23 IPIX reported Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron (B.1.1.529) and Delta (B.1.617.2) variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma (P.1) and Alpha (B.1.1.7) variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). Identifying COVID-19 countermeasures with novel mechanisms of action is vital. SARS-CoV-2 continues to evolve at an accelerated pace, raising questions as to what the dominant variant (or sub-variant) may be this fall and winter, when infections often spike — and if today’s COVID-19 vaccines and therapeutics can maintain their effectiveness. 

Emerging SARS-CoV-2 variants, and increasingly their sub-variants, contain immunity-evading mutations. These mutations alter key parts of the SARS-CoV-2 spike protein that attach to human cells, making the virus more transmissible and potentially more virulent. Unlike other antivirals, such as monoclonal antibodies, and most vaccines, Brilacidin has been shown not to target the Spike S1 and Spike RBD regions of SARS-CoV-2, acting instead through dual-acting neutralizing and blocking antiviral properties, able to target virus and host. These antiviral traits support Brilacidin’s ability to maintain its anti-coronavirus activity and suggest Brilacidin would be less subject to resistance. Related, results from new NIH/NIAID in vitro testing of Brilacidin in over 20 acutely infectious viruses, and from the Brilacidin Phase 2 COVID-19 clinical trial, are being prepared for publication. Findings from the Rutgers’ Brilacidin research can be accessed at the link below1 and build on earlier published Brilacidin research conducted by scientists at George Mason University and at University of Arizona and University of California-San Francisco. 

In 2021, the Company completed a Phase 2 clinical trial of Brilacidin (NCT04784897) for treatment of moderate-to-severe COVID-19 patients. While the trial did not meet its primary endpoint in reducing time to sustained recovery through day 29, certain patient subgroups did show treatment benefits of Brilacidin for that primary endpoint. For example, patients treated early from onset of symptoms achieved sustained recovery more quickly (Brilacidin 5-dose group vs pooled placebo, p=0.03). To date, only a modicum of success has been demonstrated by any company conducting clinical trials in moderate-to-severe hospitalized cases of COVID-19. A possible reason for this may be owing to frequent changes in the standard of care with patients receiving a cocktail of fluctuating concomitant medications, which complicates the interpretation of the clinical trial data and that of the new drug candidate being evaluated. Clinical observations of COVID-19 patients treated with Brilacidin further lead us to believe that higher and more frequent dosing of Brilacidin may be more appropriate to tackle this complex disease in the hospital setting. 

Taken together, the results from NIH/NIAID testing of Brilacidin are supportive of previously completed research and give the Company confidence in the compound’s antiviral potential. The Company remains active in pursuing additional government-based funding opportunities, as well as licensing partnerships, to advance Brilacidin in the highly attractive area of developing novel broad-spectrum medicines for treating viral diseases. 

For More on IPIX Subscribe Right Now!

Currently trading at an $18 million market valuation IPIX has $8.7 million in the treasury, over $11 million in assets vs. $4.5 million in total liabilities. IPIX is CTIX reincarnated and this stock can move skyrocketing to $4.93 per share back in the day; a run we reported on from the beginning. IPIX is heating up and getting noticed by investors after the Company reported Brilacidin, its defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity, inhibited the Omicron and Delta variants of SARS-CoV-2 based on in vitro testing conducted in collaboration with (NIH) and (NIAID) scientists. Researchers at Rutgers University have also shown Brilacidin inhibited in vitro the Gamma and Alpha variants of SARS-CoV-2. Brilacidin has now been tested in vitro in seven SARS-CoV-2 strains (Omicron, Delta, Gamma, Alpha, Italian, Washington, Wuhan) and three human coronavirus (H-CoV) strains (OC43, 229E, and NL63), in addition to MERS-CoV and SARS-CoV-1. Brilacidin has consistently inhibited all coronaviruses tested, independent of cell type, at generally attainable systemic concentrations (based on established human pharmacokinetics of IV-administered Brilacidin). We will be updating on IPIX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with IPIX.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in IPIX either long or short and we have not been compensated for this article.

The post Innovation Pharmaceuticals Inc (OTCMKTS: IPIX) Breaking Out as Biotech Reports Brilacidin Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants Based on In Vitro Testing first appeared on Micro Cap Daily.

Read More

Continue Reading

Trending